Targeted drug delivery using an aptamer against shared tumor-specific peptide antigen of MAGE-A3

References

• Shafei A, El-Bakly W, Sobhy A, Wagdy O, Reda A, Aboelenin O, Marzouk A, El Habak K, Mostafa R, Ali MA, et al. A review on the efficacy and toxicity of different doxorubicin nanoparticles for targeted therapy in metastatic breast cancer. Biomed Pharmacother. 2017;95:1209–1218. doi:10.1016/j.biopha.2017.09.059.
   PubMed Web of Science ®Google Scholar
• McGowan JV, Chung R, Maulik A, Piotrowska I, Walker JM, Yellon DM. Anthracycline chemotherapy and cardiotoxicity. Cardiovasc Drugs Ther. 2017;31(1):63–75. doi10.1007/s10557-016-6711-0.
   PubMed Web of Science ®Google Scholar
• Sheikh SE, Marsh C, Dakhlallah D. Aptamer technology in the targeted delivery of doxorubicin. Theranostics Can Res. 2017;1:1. doi:10.31031/NACS.2017.01.000502.
   Google Scholar
• Gilad Y, Firer M, Gellerman G. Recent innovations in peptide based targeted drug delivery to cancer cells. Biomedicines. 2016;4(2):E11. doi10.3390/biomedicines4020011.
   PubMed Web of Science ®Google Scholar
• Baudino TA. Targeted cancer therapy: the next generation of cancer treatment. Curr Drug Discov Technol. 2015;12(1):3–20. doi10.2174/1570163812666150602144310.
   PubMedGoogle Scholar
• Neefjes J, Jongsma ML, Paul P, Bakke O. Towards a systems understanding of MHC class I and MHC class II antigen presentation. Nat Rev Immunol. 2011;11(12):823–836. doi10.1038/nri3084.
   PubMed Web of Science ®Google Scholar
• Knight JC. Genomic modulators of the immune response. Trends Genet. 2013;29(2):74–83. doi10.1016/j.tig.2012.10.006.
   PubMed Web of Science ®Google Scholar
• Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res. 2009;15(17):5323–5337. doi:10.1158/1078-0432.CCR-09-0737.
   PubMed Web of Science ®Google Scholar
• Cancer Research Institute. Peptide database; [accessed 2016 Jul 27]. https://www.cancerresearch.org/scientists/events-and-resources/peptide-database.
   Google Scholar
• Meek DW, Marcar L. MAGE-A antigens as targets in tumour therapy. Cancer Lett. 2012;324(2):126–132. doi10.1016/j.canlet.2012.05.011.
   PubMed Web of Science ®Google Scholar
• Wang CY, Lin BL, Chen CH. An aptamer targeting shared tumor-specific peptide antigen of MAGE-A3 in multiple cancers. Int J Cancer. 2016;138(4):918–926. doi10.1002/ijc.29826.
   PubMed Web of Science ®Google Scholar
• Vorobyeva M, Vorobjev P, Venyaminova A. Multivalent aptamers: versatile tools for diagnostic and therapeutic applications. Molecules. 2016;21(12):E1613. doi10.3390/molecules21121613.
   PubMed Web of Science ®Google Scholar
• Mercier MC, Dontenwill M, Choulier L. Selection of nucleic acid aptamers targeting tumor cell-surface protein biomarkers. Cancers (Basel). 2017;9(6):E69. doi10.3390/cancers9060069.
   PubMed Web of Science ®Google Scholar
• Catuogno S, Esposito CL, de Franciscis V. Aptamer-mediated targeted delivery of therapeutics: an update. Pharmaceuticals (Basel). 2016;9(4):E69. doi10.3390/ph9040069.
   PubMedGoogle Scholar
• Ristau BT, O’Keefe DS, Bacich DJ. The prostate-specific membrane antigen: lessons and current clinical implications from 20 years of research. Urol Oncol. 2014;32(3):272–279. doi10.1016/j.urolonc.2013.09.003.
   PubMed Web of Science ®Google Scholar
• Almasi F, Mousavi Gargari SL, Bitaraf F, Rasoulinejad S. Development of a single stranded DNA aptamer as a molecular probe for LNCap cells using cell-SELEX. Avicenna J Med Biotechnol. 2016;8(3):104–111. PMCID: PMC4967543.
   PubMedGoogle Scholar
• Hwang JY, Kim ST, Han HS, Kim K, Han JS. Optical aptamer probes of fluorescent imaging to rapid monitoring of circulating tumor cell. Sensors (Basel). 2016;16(11):E1909. doi10.3390/s16111909.
   PubMed Web of Science ®Google Scholar
• Hu Y, Duan J, Zhan Q, Wang F, Lu X, Yang XD. Novel MUC1 aptamer selectively delivers cytotoxic agent to cancer cells in vitro. PLoS One. 2012;7(2):e31970. doi10.1371/journal.pone.0031970.
   PubMed Web of Science ®Google Scholar
• Girvan AC, Teng Y, Casson LK, Thomas SD, Jüliger S, Ball MW, Klein JB, Pierce WM Jr, Barve SS, Bates PJ. AGRO100 inhibits activation of nuclear factor-kappaB (NF-kappaB) by forming a complex with NF-kappaB essential modulator (NEMO) and nucleolin. Mol Cancer Ther. 2006;5(7):1790–1799. doi10.1158/1535-7163.MCT-05-0361.
   PubMed Web of Science ®Google Scholar
• Reyes-Reyes EM, Teng Y, Bates PJ. A new paradigm for aptamer therapeutic AS1411 action: uptake by macropinocytosis and its stimulation by a nucleolin-dependent mechanism. Cancer Res. 2010;70(21):8617–8629. doi10.1158/0008-5472.CAN-10-0920.
   PubMed Web of Science ®Google Scholar
• Jiang F, Liu B, Lu J, Li F, Li D, Liang C, Dang L, Liu J, He B, Badshah SA, et al. Progress and challenges in developing aptamer-functionalized targeted drug delivery systems. Int J Mol Sci. 2015;16(10):23784–23822. doi:10.3390/ijms161023784.
   PubMed Web of Science ®Google Scholar
• Huang J, Lyu H, Wang J, Liu B. Influence of survivin-targeted therapy on chemosensitivity in the treatment of acute myeloid leukemia. Cancer Lett. 2015;366(2):160–172. doi10.1016/j.canlet.2015.05.033.
   PubMed Web of Science ®Google Scholar
• Miyazaki K. Treatment of diffuse large B-cell lymphoma. J Clin Exp Hematop. 2016;56(2):79–88. doi10.3960/jslrt.56.79.
   PubMed Web of Science ®Google Scholar
• Galsky MD, Pal SK, Chowdhury S, Harshman LC, Crabb SJ, Wong YN, Yu EY, Powles T, Moshier EL, Ladoire S, et al. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer. Cancer. 2015;121(15):2586–2593. doi:10.1002/cncr.29387.
   PubMed Web of Science ®Google Scholar
• Zhao M, Ding X, Shen J, Zhang XP, Ding XW, Xu B. Use of liposomal doxorubicin for adjuvant chemotherapy of breast cancer in clinical practice. J Zhejiang Univ Sci B. 2017;18(1):15–26. doi10.1631/jzus.B1600303.
   PubMed Web of Science ®Google Scholar
• Peng Z, Wang C, Fang E, Lu X, Wang G, Tong Q, Rozhkova EA. Co-delivery of doxorubicin and SATB1 shRNA by thermosensitive magnetic cationic liposomes for gastric cancer therapy. PLoS One. 2014;9(3):e92924. doi10.1371/journal.pone.0092924.
   PubMed Web of Science ®Google Scholar
• Staropoli N, Ciliberto D, Botta C, Fiorillo L, Grimaldi A, Lama S, Caraglia M, Salvino A, Tassone P, Tagliaferri P. Pegylated liposomal doxorubicin in the management of ovarian cancer. Cancer Biol Ther. 2014;15(6):707–720. doi10.4161/cbt.28557.
   PubMed Web of Science ®Google Scholar
• Fan X, Wang L, Guo Y, Xiong X, Zhu L, Fang K. Inhibition of prostate cancer growth using doxorubicin assisted by ultrasound-targeted nanobubble destruction. Int J Nanomedicine. 2016;11:3585–3596. doi:10.2147/IJN.S111808.
   PubMed Web of Science ®Google Scholar
• Brown KT, Do RK, Gonen M, Covey AM, Getrajdman GI, Sofocleous CT, Jarnagin WR, D’Angelica MI, Allen PJ, Erinjeri JP, et al. Randomized trial of hepatic artery embolization for hepatocellular carcinoma using doxorubicin-eluting microspheres compared with embolization with microspheres alone. J Clin Oncol. 2016;34(17):2046–2053. doi:10.1200/JCO.2015.64.0821.
   PubMed Web of Science ®Google Scholar
• Melguizo C, Cabeza L, Prados J, Ortiz R, Caba O, Rama AR, ÁV D, Arias JL. Enhanced antitumoral activity of doxorubicin against lung cancer cells using biodegradable poly(butylcyanoacrylate) nanoparticles. Drug Des Devel Ther. 2015;9:6433–6444. doi:10.2147/DDDT.S92273.
   PubMed Web of Science ®Google Scholar
• Yu G, Li H, Yang S, Wen J, Niu J, Zu Y. ssDNA aptamer specifically targets and selectively delivers cytotoxic drug doxorubicin to HepG2 cells. PLoS One. 2016;11(1):e0147674. doi10.1371/journal.pone.0147674.
   PubMed Web of Science ®Google Scholar
• Champanhac C, Teng IT, Cansiz S, Zhang L, Wu X, Zhoa Z, Fu T, Tan W. Development of a panel of DNA aptamers with high affinity for pancreatic ductal adenocarcinoma. Sci Rep. 2015;5:16788. doi:10.1038/srep16788.
   PubMed Web of Science ®Google Scholar
• Trinh TL, Zhu G, Xiao X, Puszyk W, Sefah K, Wu Q, Tan W, Liu C, Ray RB. A synthetic aptamer-drug adduct for targeted liver cancer therapy. PLoS One. 2015;10(11):e0136673. doi10.1371/journal.pone.0136673.
   PubMed Web of Science ®Google Scholar
• Bagalkot V, Farokhzad OC, Langer R, Jon S. An aptamer–doxorubicin physical conjugate as a novel targeted drug-delivery platform. Angew Chem Int Ed Engl. 2006;45(48):8149–8152. doi10.1002/anie.200602251.
   PubMed Web of Science ®Google Scholar
• Cutts SM, Nudelman A, Rephaeli A, Phillips DR. The power and potential of doxorubicin-DNA adducts. IUBMB Life. 2005;57(2):73–81. doidoi:10.1081/15216540500079093..
   PubMed Web of Science ®Google Scholar
• Chang MC, Ho YS, Lee PH, Chan CP, Lee JJ, Hahn LJ, Wang YJ, Jeng JH. Areca nut extract and arecoline induced the cell cycle arrest but not apoptosis of cultured oral KB epithelial cells: association of glutathione, reactive oxygen species and mitochondrial membrane potential. Carcinogenesis. 2001;22(9):1527–1535. doi10.1093/carcin/22.9.1527.
   PubMed Web of Science ®Google Scholar
• Chaires JB, Herrera JE, Waring MJ. Preferential binding of daunomycin to 5’eq \o(\s\up 6(A),\s\do 2(T))CG and 5’eq \o(\s\up 6(A),\s\do 2(T))GC sequences revealed by footprinting titration experiments. Biochemistry. 1990;29:6145–6153. doi:10.1021/bi00478a006.
   PubMed Web of Science ®Google Scholar
• Fueger BJ, Hamilton G, Raderer M, Pangerl T, Traub T, Angelberger P, Baumgartner G, Dudczak R, Virgolini I. Effects of chemotherapeutic agents on expression of somatostatin receptors in pancreatic tumor cells. J Nucl Med. 2001;42(12):1856–1862. PMID:11752085.
   PubMed Web of Science ®Google Scholar
• Al-Nasiry S, Geusens N, Hanssens M, Luyten C, Pijnenborg R. The use of Alamar Blue assay for quantitative analysis of viability, migration and invasion of choriocarcinoma cells. Hum Reprod. 2007;22(5):1304–1309. doi10.1093/humrep/dem011.
   PubMed Web of Science ®Google Scholar
• Erkan M, Hausmann S, Michalski CW, Fingerle AA, Dobritz M, Kleeff J, Friess H. The role of stroma in pancreatic cancer: diagnostic and therapeutic implications. Nat Rev Gastroenterol Rev Hepatol. 2012;9(8):454–467. doi10.1038/nrgastro.2012.115.
   PubMed Web of Science ®Google Scholar
• Koay EJ, Baio FE, Ondari A, Truty MJ, Cristini V, Thomas RM, Chen R, Chatterjee D, Kang Y, Zhang J, et al. Intra-tumoral heterogeneity of gemcitabine delivery and mass transport in human pancreatic cancer. Phys Biol. 2014;11(6):065002. doi:10.1088/1478-3975/11/6/065002.
   PubMed Web of Science ®Google Scholar
• Peng CG, Damha MJ. G-quadruplex induced stabilization by 2ʹ-deoxy-2ʹ-fluoro-D- arabinonucleic acids (2ʹF-ANA). Nucleic Acids Res. 2007;35(15):4977–4988. doi10.1093/nar/gkm520.
   PubMed Web of Science ®Google Scholar